Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Capricor Therapeutics (CAPR) over the last 16 years, with Q3 2025 value amounting to $494726.0.

  • Capricor Therapeutics' Depreciation & Amortization (CF) rose 3697.95% to $494726.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 2984.58%. This contributed to the annual value of $1.4 million for FY2024, which is 3333.69% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Depreciation & Amortization (CF) of $494726.0 as of Q3 2025, which was up 3697.95% from $486278.0 recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Depreciation & Amortization (CF) peaked at $494726.0 during Q3 2025, and registered a low of $50137.0 during Q1 2021.
  • In the last 5 years, Capricor Therapeutics' Depreciation & Amortization (CF) had a median value of $254702.0 in 2023 and averaged $245230.4.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 14878.47% in 2023, then surged by 2213.76% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Depreciation & Amortization (CF) stood at $78645.0 in 2021, then soared by 143.63% to $191602.0 in 2022, then soared by 60.55% to $307608.0 in 2023, then grew by 22.14% to $375705.0 in 2024, then skyrocketed by 31.68% to $494726.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $494726.0 for Q3 2025, versus $486278.0 for Q2 2025 and $405450.0 for Q1 2025.